Edition:
United Kingdom

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

405.00GBp
24 Jan 2018
Change (% chg)

-5.20 (-1.27%)
Prev Close
410.20
Open
409.30
Day's High
409.50
Day's Low
404.20
Volume
182,504
Avg. Vol
2,687,090
52-wk High
436.60
52-wk Low
246.50

Chart for

About

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue... (more)

Overall

Beta: --
Market Cap(Mil.): £2,498.61
Shares Outstanding(Mil.): 721.46
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.62
EPS (TTM): -- -- --
ROI: -- 14.89 10.61
ROE: -- 16.37 14.21

Indivior replaces $484 million in dollar, euro debt facilities

British drugmaker Indivior said it replaced all of its U.S. dollar and euro denominated outstanding term loans of about $484 million (£362 million).

19 Dec 2017

UK's Indivior replaces $484 mln in dollar, euro debt facilities

Dec 19 British drugmaker Indivior said it replaced all of its U.S. dollar and euro denominated outstanding term loans of about $484 million.

19 Dec 2017

BRIEF-‍Indivior Says Repricing And Maturity Extension Of Term Loan Facilities

* ‍INDIVIOR ANNOUNCES REPRICING AND MATURITY EXTENSION OF TERM LOAN FACILITIES AND REPLACEMENT OF CREDIT FACILITY​

19 Dec 2017

BRIEF-Indivior Announces NDA Acceptance Of RBP-7000 Risperidone Monthly Depot

* INDIVIOR ANNOUNCES NDA ACCEPTANCE OF RBP-7000 RISPERIDONE MONTHLY DEPOT

12 Dec 2017

U.S. FDA accepts application for Indivior's new schizophrenia drug

U.S. Food and Drug Administration (FDA) accepted Indivior's application for its new schizophrenia treatment, the British drugmaker said on Tuesday, boosting hopes of marketing the drug in the country.

12 Dec 2017

U.S. FDA accepts application for Indivior's new schizophrenia drug

Dec 12 U.S. Food and Drug Administration (FDA) accepted Indivior's application for its new schizophrenia treatment, the British drugmaker said on Tuesday, boosting hopes of marketing the drug in the country.

12 Dec 2017

BRIEF-‍Indivior Says FDA Accepts Application For New Schizophrenia Drug

* ‍INDIVIOR ANNOUNCES NDA ACCEPTANCE OF RBP-7000 RISPERIDONE MONTHLY DEPOT​

12 Dec 2017

LPC-Indivior launches US$485m-equiv loan refi

LONDON, Dec 5 Pharmaceuticals company Indivior has launched a US$485m-equivalent loan to refinance existing debt, banking sources said.

05 Dec 2017

Indivior drug to fight opioid addiction approved by U.S. FDA

Indivior's experimental drug to help fight America's growing opioid addiction crisis was approved by the U.S. Food and Drug Administration late on Thursday, boosting its sales prospects as competitors threaten revenues from an older product.

01 Dec 2017

FTSE falls in broad risk-off move as Trump worries resurface

LONDON The FTSE fell on Friday at the end of a choppy session that saw Britain's top-share index accelerate losses and join a global risk-off move following reports in the United States that raised new worries over the stability of Donald Trump's administration.

01 Dec 2017

Earnings vs. Estimates